Publications by authors named "Daphne B Scarpelli"
Exploring the Role of Resection Post-Radiation Therapy in Gliomas.
Int J Radiat Oncol Biol Phys
May 2022
Article Synopsis
- A case study of a 6-year-old girl presented severe symptoms from a high-grade AVM, leading to surgery and initial SRS treatment, but she later developed recurrent symptoms due to a new AVM nidus.
- The treatment for her persistent RIN shifted from steroids to bevacizumab, resulting in a significant improvement in her symptoms and reduced side effects associated with long-term steroid use.
Article Synopsis
- The study analyzed demographics, treatment methods, and outcomes for meningeal melanocytomas using data from the National Cancer Database for cases from 2002 to 2016.
- The results showed a median survival of about 57 months and a 5-year overall survival rate of 48%, with higher income correlating with better survival outcomes.
- Although surgery was the primary treatment, radiotherapy was given to 37.7% of patients but did not improve survival; limitations in treatment data affected further analysis.
Single-fraction stereotactic radiosurgery (SRS) is a highly used tool in managing brain metastases, alongside its multifraction counterpart - stereotactic body radiation therapy (SBRT). These radiation therapy techniques have been associated with excellent clinical outcomes, such as decreased local recurrence, increased survival, and improved palliative effects. However, present literature concerning the cost-effectiveness of these techniques remain scarce.
View Article and Find Full Text PDFBackground: Pleomorphic xanthoastrocytomas (PXAs) account for <1% of primary brain tumors, occurring predominantly in children and young adults. Surgical resection serves as the primary treatment for PXAs, while radiotherapy (RT) and chemotherapy protocols remain poorly defined.
Aim: This study aims to determine current care patterns utilized for pediatric patients (≤ 18 years) diagnosed with PXAs and their effect on overall survival.
Myxopapillary ependymomas (MPE) are WHO Grade I ependymomas that annually occur in 0.05-0.08 per 100,000 people.
View Article and Find Full Text PDF